DelveInsight’s “PDE4 Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the PDE4 Inhibitors, historical and competitive landscape as well as the PDE4 Inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The PDE4 inhibitor market is poised for substantial growth in the coming years, driven by expanding research in inflammatory and autoimmune diseases.
Discover which therapies are expected to grab the PDE4 inhibitor market share @ https://www.delveinsight.com/sample-request/phosphodiesterase-4-pde4-inhibitor-market-forecast
Key Takeaways from the PDE4 Inhibitor Market Report
- In July 2025, Merck announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per ADS, each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately USD 10 billion.
- As per DelveInsight’s analysis, the PDE4 inhibitor market is anticipated to grow at a significant CAGR by 2034.
- The leading PDE4 Inhibitor Companies such as UNION therapeutics, Chiesi Farmaceutici S.p.A., Amgen, Tetra Discovery Partners, Takeda, Bristol-Myers Squibb, Pfizer, and others.
- Promising PDE4 Inhibitors Therapioes include Orismilast modified release tablets, CHF6001, Otezla, Zatolmilast, TAK-279, PF-07038124, and Deucravacitinib, and others.
Learn more about the FDA-approved PDE4 inhibitor @ PDE4 Inhibitor Drugs
PDE4 Inhibitor Epidemiology Segmentation
- Total Prevalent Cases of Selected Indications (Chronic obstructive pulmonary disease, Atopic Dermatitis, Plaque Psoriasis, Psoriatic Arthritis, and others)
- Total Eligible Patient Pool for PDE4 Inhibitors in Selected Indications
- Total Treated Cases in Selected Indications for PDE4 Inhibitors
Download the report to understand what epidemiologists are saying about how PDE4 inhibitor patient trends in 7MM @ PDE4 Inhibitor Prevalence
PDE4 Inhibitors Marketed Drugs
- ZORYVE (roflumilast): Arcutis Biotherapeutics
ZORYVE is a next-generation topical PDE4 inhibitor developed by Arcutis Biotherapeutics. Targeting PDE4, a key enzyme in inflammation, roflumilast reduces pro-inflammatory mediators while enhancing anti-inflammatory responses. Available in both cream and foam formulations, ZORYVE offers a non-steroidal treatment option with favorable tolerability for chronic dermatologic conditions like plaque psoriasis, atopic dermatitis (AD), and seborrheic dermatitis. ZORYVE first got FDA approvals as cream 0.3% for plaque psoriasis in July 2022 and after that it got multiple approvals for pediatric psoriasis ages 6–11yr (October 2023), cream 0.15% for mild to moderate atopic dermatitis in patients 6 and older (July 2024); and foam 0.3% for seborrheic dermatitis in individuals aged 9 and older (December 2023). These approvals broaden ZORYVE’s reach across age groups and dermatologic indications.
- EUCRISA (crisaborole): Pfizer
Eucrisa (crisaborole) is a topical phosphodiesterase 4 (PDE-4) inhibitor approved for the treatment of mild to moderate atopic dermatitis in adults and children as young as 3 months old. It is the first and only non-steroidal topical monotherapy designed to inhibit the PDE-4 enzyme in the skin. Overactivity of this enzyme is believed to play a role in the signs and symptoms of atopic dermatitis. While the exact mechanism of crisaborole in treating the condition is not fully understood, its ability to target PDE-4 is a key factor in its therapeutic effect. It first got FDA approval in December 2016 for the treatment of Eczema. It also received additional approval from the FDA for use in children 3 months and older with mild to moderate atopic dermatitis.
PDE4 Inhibitor Emerging Drugs
- Zatolmilast: Shionogi
Zatolmilast is the first selective PDE4D inhibitor being investigated for Fragile X syndrome (FXS), a genetic disorder causing intellectual disability and developmental delays. There are no FDA-approved treatments for FXS, and zatolmilast’s development represents a potential breakthrough. It has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Tetra Therapeutics is conducting clinical trials for Fragile X syndrome to assess zatolmilast’s safety and efficacy. The trials, including Phase 3 studies, focus on improving cognition and daily functioning in FXS patients. Positive early-phase results suggest that zatolmilast may provide significant benefits, offering hope for a much-needed cognitive treatment option for individuals with this rare genetic disorder.
- PALI-2108: Palisade Bio
PALI-2108 is an orally administered, colon-targeted PDE4 inhibitor prodrug being developed by Palisade Bio for ulcerative colitis (UC). It supports a precision medicine approach aimed at identifying patient responders for future studies. The drug is designed for local action in the colon, minimizing systemic exposure and potential side effects. A Phase 1 study is currently evaluating PALI-2108’s safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Preliminary results from the first three cohorts (15mg, 50mg, and 150mg) in healthy volunteers show that the drug was well tolerated with no dose-limiting toxicities or treatment-related dose reductions, supporting continued clinical development in ulcerative colitis patients.
To know more about PDE4 inhibitor clinical trials, visit @ PDE4 Inhibitor Treatment Drugs
PDE4 Inhibitor Market Outlook
The PDE4 inhibitors market is expected to witness steady growth through 2034, driven by rising cases of chronic inflammatory and autoimmune diseases such as psoriasis, atopic dermatitis, and COPD. PDE4 inhibitors offer targeted, non-steroidal anti-inflammatory effects with oral or topical administration, making them attractive alternatives to traditional therapies. Factors such as expanding indications, patient preference for non-invasive treatments, and improved safety profiles are accelerating market adoption across key regions, including the U.S., Europe, and Japan. Currently approved PDE4 inhibitors include OTEZLA (apremilast), EUCRISA (crisaborole), ZORYVE (roflumilast), and others, which address conditions like psoriasis, atopic dermatitis, and eczema. OTEZLA leads the market with over USD 2.1 billion in 2024 revenue and expanded pediatric approval. ZORYVE has shown rapid uptake across multiple formulations, reaching over 600,000 prescriptions since launch. EUCRISA remains widely used in both pediatric and adult populations. These therapies reflect the class’s strong market presence and evolving treatment versatility.
PDE4 Inhibitor Market Dynamics
The PDE4 Inhibitors market dynamics exhibit a fascinating interplay between pharmaceutical innovation, regulatory landscapes, and therapeutic demand. These inhibitors, targeting the phosphodiesterase 4 enzyme, have garnered significant attention due to their potential in treating a spectrum of inflammatory and autoimmune disorders. One notable aspect driving market dynamics is the ever-evolving understanding of the role of PDE4 in various physiological processes, which constantly unveils new therapeutic opportunities and expands the potential market.
Discover more about PDE4 inhibitor drugs in development @ PDE4 Inhibitor Clinical Trials
Scope of the PDE4 Inhibitor Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Companies- UNION Therapeutics, Chiesi Farmaceutici S.p.A., Amgen, Tetra Discovery Partners, Takeda, Bristol-Myers Squibb, Pfizer, and others.
- PDE4 Inhibitor Therapeutic Assessment: PDE4 Inhibitor current marketed and emerging therapies
- PDE4 Inhibitor Market Dynamics: Attribute Analysis of Emerging PDE4 Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, PDE4 Inhibitor Market Access and Reimbursement
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Phosphodiesterase-4 (PDE4) Inhibitor
4. Key Events
5. Phosphodiesterase-4 (PDE4) Inhibitor Market Overview At A Glance
6. Background And Overview
7. Target Population
8. Phosphodiesterase-4 (PDE4) Inhibitor Marketed Drugs
9. Phosphodiesterase-4 (PDE4) Inhibitor Emerging Drugs
10. Phosphodiesterase-4 (PDE4) Inhibitor: The 7MM Analysis
11. Unmet Needs
12. SWOT Analysis
13. KOL Views
14. Market Access and Reimbursement
15. Appendix
16. DelveInsight Capabilities
18. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
